MARLBOROUGH, Mass.--(BUSINESS WIRE)--EXACT Sciences Corporation (NASDAQ: EXAS) today commented on the addition of non-invasive stool-based DNA (sDNA) testing to the state colorectal cancer screening mandates of New Jersey and Maryland, as well as the decision by CIGNA, one of the nation’s largest insurers, to include sDNA screening among its covered benefits nationally. Under insurance bulletins issued by the states of New Jersey and Maryland, available colorectal cancer (CRC) screening options offered by certain categories of insurers in these states must include all tests identified in the 2008 American Cancer Society screening guidelines, which include sDNA screening. A May 2006 analysis by the American Cancer Society found that screening rates improved forty-percent faster in states with strong reimbursement coverage laws as compared to states without such laws.
